The stock of Accuray Incorporated (NASDAQ:ARAY) is a huge mover today! About 392,641 shares traded hands. Accuray Incorporated (NASDAQ:ARAY) has declined 12.05% since April 14, 2016 and is downtrending. It has underperformed by 16.74% the S&P500.
The move comes after 5 months negative chart setup for the $463.20M company. It was reported on Nov, 16 by Barchart.com. We have $4.79 PT which if reached, will make NASDAQ:ARAY worth $60.22M less.
Accuray Incorporated (NASDAQ:ARAY) Ratings Coverage
Out of 3 analysts covering Accuray (NASDAQ:ARAY), 1 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 33% are positive. Accuray has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. Zacks upgraded the stock to “Sell” rating in Wednesday, August 5 report. On Friday, August 21 the stock rating was maintained by BTIG Research with “Neutral”. On Tuesday, September 13 the stock rating was initiated by Cowen & Co with “Outperform”. Zacks downgraded the shares of ARAY in a report on Tuesday, August 25 to “Buy” rating. The stock of Accuray Incorporated (NASDAQ:ARAY) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, December 22. RBC Capital Markets maintained the shares of ARAY in a report on Friday, January 29 with “Sector Perform” rating. The firm has “Sell” rating given on Thursday, November 12 by Citigroup.
According to Zacks Investment Research, “ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.”
Insitutional Activity: The institutional sentiment decreased to 1.12 in Q2 2016. Its down 0.17, from 1.29 in 2016Q1. The ratio dropped, as 16 funds sold all Accuray Incorporated shares owned while 35 reduced positions. 17 funds bought stakes while 40 increased positions. They now own 71.42 million shares or 12.01% less from 81.17 million shares in 2016Q1.
Moreover, Blackrock Fund Advsr has 0% invested in Accuray Incorporated (NASDAQ:ARAY) for 2.64 million shares. National Bank Of Montreal Can holds 0% of its portfolio in Accuray Incorporated (NASDAQ:ARAY) for 157 shares. Geode Cap Mngmt Limited Liability Company has 562,914 shares for 0% of their US portfolio. The Connecticut-based Trexquant Investment L P has invested 0.01% in Accuray Incorporated (NASDAQ:ARAY). Jpmorgan Chase holds 342 shares or 0% of its portfolio. Winslow Evans & Crocker has 0% invested in the company for 1,648 shares. Principal Grp holds 0% or 15,938 shares in its portfolio. Oracle Invest Mngmt accumulated 2.48 million shares or 3% of the stock. Deere And owns 84,902 shares or 0.02% of their US portfolio. Bank Of New York Mellon Corporation holds 0% or 549,815 shares in its portfolio. Birchview Capital Limited Partnership accumulated 95,300 shares or 0.36% of the stock. Sei Investments Com holds 10,729 shares or 0% of its portfolio. Cypress Cap Mgmt Ltd Liability Company (Wy) has invested 0% of its portfolio in Accuray Incorporated (NASDAQ:ARAY). Bnp Paribas Arbitrage last reported 0% of its portfolio in the stock. Moreover, Price T Rowe Md has 0% invested in Accuray Incorporated (NASDAQ:ARAY) for 2.89 million shares.
More news for Accuray Incorporated (NASDAQ:ARAY) were recently published by: Fool.com, which released: “Why Accuray Incorporated Is Tumbling 12.5% Today” on August 18, 2016. Fool.com‘s article titled: “Better Buy: Intuitive Surgical, Inc. vs. Accuray Incorporated” and published on February 10, 2016 is yet another important article.
ARAY Company Profile
Accuray Incorporated, incorporated on February 22, 2001, is a radiation oncology company. The Firm develops, makes, sells and supports treatment solutions. It develops, makes and markets medical devices used in radiation therapy for the treatment of cancer patients. The Company’s suite of products includes the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. The Company’s technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver a range of treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.